Story

Spyre Therapeutics Shares Fall as Arthritis Drug Fails to Meet Internal Efficacy Target

ENTHMSVIIDZHZH-TWJAKOHI
Aug 25, 20262 min read
Spyre Therapeutics Shares Fall as Arthritis Drug Fails to Meet Internal Efficacy Target
Text size
Background

Spyre Therapeutics (NASDAQ:SYRE) shares fell 14% in after-hours trading Tuesday after the company announced that topline results from a Phase 2 trial of its drug candidate, SPY072, did not meet the company's internal criteria to be advanced as a monotherapy for rheumatoid arthritis.

Trial Results Details

The SKYWAY Phase 2 study evaluated two doses of SPY072 against a placebo in 143 participants with rheumatoid arthritis. According to the company's release, the drug demonstrated a statistically significant benefit over placebo on certain endpoints but the overall "magnitude of effect" was not sufficient to warrant pursuing it as a standalone treatment.

Key findings from the 12-week trial include:

  • The low dose of SPY072 met the primary endpoint, showing a change from baseline in DAS28-CRP score of -1.9 versus -1.3 for placebo.
  • The high dose achieved a 63% ACR20 response rate, compared to 43% for the placebo group.
  • On the ACR50 measure, the low dose achieved a 38% response rate versus 19% for placebo.
Sample IUX Markets – In-articleAd

Spyre also reported that SPY072 was well tolerated, with adverse events occurring in 27% of participants receiving the drug compared to 36% in the placebo arm. Most events were classified as mild or moderate.

Company Outlook and Strategy

Despite the setback for the rheumatoid arthritis monotherapy program, Spyre stated that the results support the potential of its TL1A antibodies, particularly as part of combination therapies for autoimmune diseases. The company confirmed it would not prioritize the development of SPY072 as a standalone treatment for rheumatoid arthritis based on these findings.

Investors will now look ahead to further data readouts for SPY072. The company expects topline results for the drug in psoriatic arthritis and axial spondyloarthritis in the fourth quarter of 2026. Data for SPY072 in combination with an IL-17A/F inhibitor for hidradenitis suppurativa is anticipated in late 2027 or early 2028.

Read next

More on Stocks
Back to latest news

LATEST